EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Pembrolizumab Plus Lenvatinib in Metastatic Renal Cell Carcinoma: Real-world Prognostic Factors

Shimpei Yamashita, Takeshi Yamasaki, Kosuke Ueda, Ryotaro Tomida, Shingo Toyoda, Hiroaki Iwamoto, Makito Miyake, Ikko Tomisaki, Shuichi Morizane, Yasuo Kohjimoto

Anticancer Research · 2026-08 · 46 (8) · 4489-4497

DOI: 10.21873/anticanres.18305 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Anticancer Research, online erschienen am 29.07.2026. Verfasst von Shimpei Yamashita und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Wakayama Medical University, Wakayama, Japan; keito608@wakayama-med.ac.jp. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Kidney Neoplasms.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Renal CellKidney NeoplasmsPhenylurea CompoundsQuinolinesAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm MetastasisPrognosisProgression-Free SurvivalRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

Renal cell carcinomalenvatinibpembrolizumabprogression-free survivalreal-world data

Substanzen

Antibodies, Monoclonal, HumanizedlenvatinibpembrolizumabPhenylurea CompoundsQuinolines

Autor:innen und Institutionen

  • Department of Urology, Wakayama Medical University, Wakayama, Japan; keito608@wakayama-med.ac.jp.
  • Department of Urology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
  • Department of Urology, Kurume University School of Medicine, Kurume, Japan.
  • Department of Urology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
  • Department of Urology, Kindai University Faculty of Medicine, Osakasayama, Japan.
  • Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.

Zitieren

APA

Yamashita, S., Yamasaki, T., Ueda, K., Tomida, R., Toyoda, S., Iwamoto, H., Miyake, M., Tomisaki, I., Morizane, S., & Kohjimoto, Y. (2026). Pembrolizumab Plus Lenvatinib in Metastatic Renal Cell Carcinoma: Real-world Prognostic Factors. Anticancer Research, 46(8), 4489-4497. https://doi.org/10.21873/anticanres.18305

Vancouver

Yamashita S, Yamasaki T, Ueda K, Tomida R, Toyoda S, Iwamoto H, et al. Pembrolizumab Plus Lenvatinib in Metastatic Renal Cell Carcinoma: Real-world Prognostic Factors. Anticancer Research. 2026;46(8):4489-4497. doi:10.21873/anticanres.18305

BibTeX
@article{Yamashita2026,
  author = {Yamashita, Shimpei and Yamasaki, Takeshi and Ueda, Kosuke and Tomida, Ryotaro and Toyoda, Shingo and Iwamoto, Hiroaki and Miyake, Makito and Tomisaki, Ikko and Morizane, Shuichi and Kohjimoto, Yasuo},
  title = {Pembrolizumab Plus Lenvatinib in Metastatic Renal Cell Carcinoma: Real-world Prognostic Factors},
  journal = {Anticancer Research},
  year = {2026},
  volume = {46},
  number = {8},
  pages = {4489--4497},
  doi = {10.21873/anticanres.18305}
}
Kostenlos starten →